Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.57
AZN's Cash to Debt is ranked higher than
60% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. AZN: 0.57 )
AZN' s 10-Year Cash to Debt Range
Min: 0.2   Max: No Debt
Current: 0.57

Equity to Asset 0.38
AZN's Equity to Asset is ranked higher than
52% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. AZN: 0.38 )
AZN' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.59
Current: 0.38

0.3
0.59
Interest Coverage 7.50
AZN's Interest Coverage is ranked higher than
54% of the 490 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 89.59 vs. AZN: 7.50 )
AZN' s 10-Year Interest Coverage Range
Min: 6.94   Max: 100.5
Current: 7.5

6.94
100.5
F-Score: 4
Z-Score: 2.63
M-Score: -3.37
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 11.82
AZN's Operating margin (%) is ranked higher than
79% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.55 vs. AZN: 11.82 )
AZN' s 10-Year Operating margin (%) Range
Min: 12.32   Max: 38.09
Current: 11.82

12.32
38.09
Net-margin (%) 7.82
AZN's Net-margin (%) is ranked higher than
78% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.93 vs. AZN: 7.82 )
AZN' s 10-Year Net-margin (%) Range
Min: 6.86   Max: 29.72
Current: 7.82

6.86
29.72
ROE (%) 8.79
AZN's ROE (%) is ranked higher than
78% of the 792 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.26 vs. AZN: 8.79 )
AZN' s 10-Year ROE (%) Range
Min: 10.72   Max: 45.6
Current: 8.79

10.72
45.6
ROA (%) 3.54
AZN's ROA (%) is ranked higher than
72% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.06 vs. AZN: 3.54 )
AZN' s 10-Year ROA (%) Range
Min: 4.6   Max: 21.04
Current: 3.54

4.6
21.04
ROC (Joel Greenblatt) (%) 51.06
AZN's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.08 vs. AZN: 51.06 )
AZN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 33.33   Max: 192.75
Current: 51.06

33.33
192.75
Revenue Growth (%) -5.10
AZN's Revenue Growth (%) is ranked higher than
56% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. AZN: -5.10 )
AZN' s 10-Year Revenue Growth (%) Range
Min: -54.5   Max: 87.7
Current: -5.1

-54.5
87.7
EBITDA Growth (%) -14.50
AZN's EBITDA Growth (%) is ranked higher than
57% of the 640 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.20 vs. AZN: -14.50 )
AZN' s 10-Year EBITDA Growth (%) Range
Min: -40.8   Max: 112.8
Current: -14.5

-40.8
112.8
EPS Growth (%) -29.50
AZN's EPS Growth (%) is ranked higher than
57% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. AZN: -29.50 )
AZN' s 10-Year EPS Growth (%) Range
Min: -29.5   Max: 71.5
Current: -29.5

-29.5
71.5
» AZN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

AZN Guru Trades in Q3 2013

Steven Cohen 532,113 sh (+4346.87%)
Pioneer Investments 590,122 sh (+23.7%)
Charles Brandes 2,381,040 sh (+7.92%)
David Dreman 179,261 sh (+4.4%)
Murray Stahl 12,020 sh (+0.17%)
NWQ Managers 85,850 sh (unchged)
Manning & Napier Advisors, Inc 508,945 sh (-0.53%)
HOTCHKIS & WILEY 4,912,449 sh (-0.65%)
Jim Simons 2,913,800 sh (-14.94%)
John Hussman 68,000 sh (-81.87%)
» More
Q4 2013

AZN Guru Trades in Q4 2013

Francis Chou 13,000 sh (New)
Stanley Druckenmiller 360,500 sh (New)
Pioneer Investments 651,839 sh (+10.46%)
Charles Brandes 2,503,848 sh (+5.16%)
Steven Cohen 533,262 sh (+0.22%)
Murray Stahl 12,020 sh (unchged)
NWQ Managers 85,450 sh (-0.47%)
Manning & Napier Advisors, Inc 490,878 sh (-3.55%)
Jim Simons 2,715,400 sh (-6.81%)
HOTCHKIS & WILEY 3,689,214 sh (-24.9%)
David Dreman 106,975 sh (-40.32%)
John Hussman 28,000 sh (-58.82%)
» More
Q1 2014

AZN Guru Trades in Q1 2014

Joel Greenblatt 95,518 sh (New)
John Hussman 228,000 sh (+714.29%)
David Dreman 135,439 sh (+26.61%)
Murray Stahl 13,106 sh (+9.03%)
NWQ Managers 85,450 sh (unchged)
Stanley Druckenmiller 360,500 sh (unchged)
Francis Chou 13,000 sh (unchged)
HOTCHKIS & WILEY Sold Out
Manning & Napier Advisors, Inc 459,569 sh (-6.38%)
Pioneer Investments 459,298 sh (-29.54%)
Steven Cohen 367,034 sh (-31.17%)
Charles Brandes 1,333,894 sh (-46.73%)
Jim Simons 1,429,000 sh (-47.37%)
» More
Q2 2014

AZN Guru Trades in Q2 2014

Louis Moore Bacon 40,000 sh (New)
Mario Gabelli 40,400 sh (New)
Jeremy Grantham 28,000 sh (New)
George Soros 150,000 sh (New)
Paul Tudor Jones 27,100 sh (New)
Jim Simons 1,794,800 sh (+25.6%)
Daniel Loeb 1,000,000 sh (unchged)
Steven Cohen 225,000 sh (unchged)
Francis Chou 13,000 sh (unchged)
Steven Cohen 370,800 sh (unchged)
Joel Greenblatt Sold Out
Murray Stahl 13,000 sh (-0.81%)
John Hussman 223,500 sh (-1.97%)
David Dreman 117,832 sh (-13%)
NWQ Managers 64,475 sh (-24.55%)
Manning & Napier Advisors, Inc 309,030 sh (-32.76%)
Stanley Druckenmiller 208,900 sh (-42.05%)
Pioneer Investments 225,804 sh (-50.84%)
Charles Brandes 386,058 sh (-71.06%)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2014-06-30 Reduce -71.06%0.78%$62.45 - $81.09 $ 72.050%386058
Joel Greenblatt 2014-06-30 Sold Out 0.09%$62.45 - $81.09 $ 72.050%0
George Soros 2014-06-30 New Buy0.08%$62.45 - $81.09 $ 72.050%150000
Mario Gabelli 2014-06-30 New Buy0.02%$62.45 - $81.09 $ 72.050%40400
John Hussman 2014-03-31 Add 714.29%0.96%$58.51 - $68.15 $ 72.0512%228000
Charles Brandes 2014-03-31 Reduce -46.73%0.84%$58.51 - $68.15 $ 72.0512%1333894
David Dreman 2014-03-31 Add 26.61%0.14%$58.51 - $68.38 $ 72.0512%135439
Joel Greenblatt 2014-03-31 New Buy0.09%$58.51 - $68.38 $ 72.0512%95518
David Dreman 2013-12-31 Reduce -40.32%0.34%$49.72 - $59.5 $ 72.0533%106975
John Hussman 2013-12-31 Reduce -58.82%0.11%$49.72 - $59.5 $ 72.0533%28000
John Hussman 2013-09-30 Reduce -81.87%0.66%$47.88 - $52.08 $ 72.0543%68000
Charles Brandes 2013-09-30 Add 7.92%0.12%$47.88 - $52.08 $ 72.0543%2381040
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 47.20
AZN's P/E(ttm) is ranked higher than
74% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.90 vs. AZN: 47.20 )
AZN' s 10-Year P/E(ttm) Range
Min: 6.07   Max: 47.24
Current: 47.2

6.07
47.24
P/B 4.48
AZN's P/B is ranked higher than
65% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.39 vs. AZN: 4.48 )
AZN' s 10-Year P/B Range
Min: 2.31   Max: 7.02
Current: 4.48

2.31
7.02
P/S 3.68
AZN's P/S is ranked higher than
71% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.81 vs. AZN: 3.68 )
AZN' s 10-Year P/S Range
Min: 1.6   Max: 4.13
Current: 3.68

1.6
4.13
PFCF 12.86
AZN's PFCF is ranked higher than
97% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. AZN: 12.86 )
AZN' s 10-Year PFCF Range
Min: 6.22   Max: 60.7
Current: 12.86

6.22
60.7
EV-to-EBIT 31.14
AZN's EV-to-EBIT is ranked higher than
75% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 31.14 vs. AZN: 31.14 )
AZN' s 10-Year EV-to-EBIT Range
Min: 4.5   Max: 32.7
Current: 31.14

4.5
32.7
Shiller P/E 14.48
AZN's Shiller P/E is ranked higher than
96% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.02 vs. AZN: 14.48 )
AZN' s 10-Year Shiller P/E Range
Min: 8.1   Max: 27.94
Current: 14.48

8.1
27.94
Current Ratio 0.99
AZN's Current Ratio is ranked lower than
52% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. AZN: 0.99 )
AZN' s 10-Year Current Ratio Range
Min: 0.64   Max: 2.03
Current: 0.99

0.64
2.03
Quick Ratio 0.85
AZN's Quick Ratio is ranked higher than
52% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. AZN: 0.85 )
AZN' s 10-Year Quick Ratio Range
Min: 0.54   Max: 2.03
Current: 0.85

0.54
2.03

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.00
AZN's Dividend Yield is ranked higher than
95% of the 485 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. AZN: 4.00 )
AZN' s 10-Year Dividend Yield Range
Min: 1.68   Max: 6.75
Current: 4

1.68
6.75
Dividend Payout 1.74
AZN's Dividend Payout is ranked higher than
82% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. AZN: 1.74 )
AZN' s 10-Year Dividend Payout Range
Min: 0.24   Max: 4.87
Current: 1.74

0.24
4.87
Dividend growth (3y) 3.20
AZN's Dividend growth (3y) is ranked higher than
80% of the 356 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.50 vs. AZN: 3.20 )
AZN' s 10-Year Dividend growth (3y) Range
Min: -6.3   Max: 30.1
Current: 3.2

-6.3
30.1
Yield on cost (5-Year) 5.66
AZN's Yield on cost (5-Year) is ranked higher than
95% of the 493 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. AZN: 5.66 )
AZN' s 10-Year Yield on cost (5-Year) Range
Min: 2.38   Max: 9.56
Current: 5.66

2.38
9.56
Share Buyback Rate 4.60
AZN's Share Buyback Rate is ranked higher than
92% of the 584 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.30 vs. AZN: 4.60 )
AZN' s 10-Year Share Buyback Rate Range
Min: 43.7   Max: -144.8
Current: 4.6

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.14
AZN's Price/DCF (Projected) is ranked higher than
94% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.02 vs. AZN: 1.14 )
AZN' s 10-Year Price/DCF (Projected) Range
Min: 0.49   Max: 4.45
Current: 1.14

0.49
4.45
Price/Median PS Value 1.55
AZN's Price/Median PS Value is ranked higher than
63% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.27 vs. AZN: 1.55 )
AZN' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 2.48
Current: 1.55

0.7
2.48
Earnings Yield (Greenblatt) 3.20
AZN's Earnings Yield (Greenblatt) is ranked higher than
65% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. AZN: 3.20 )
AZN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 22.2
Current: 3.2

3.1
22.2
Forward Rate of Return (Yacktman) -0.25
AZN's Forward Rate of Return (Yacktman) is ranked higher than
68% of the 668 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. AZN: -0.25 )
AZN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.8   Max: 30.1
Current: -0.25

-1.8
30.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:AZN.Sweden, AZNDF.USA, AZN.UK, ZEGA.Germany, ZEG.Germany, AZNCF.USA
AstraZeneca PLC is engaged in the global, prescription-based biopharmaceutical business. Its pharmaceuticals business consists of the discovery and development of new products, which are then manufactured, marketed and sold. It focuses on six therapy areas of healthcare such as Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory & Inflammation. The Company has operations in the United Kingdom, Continental Europe, The Americas, Asia, Africa, and Australia.
» More Articles for NYSE:AZN

Headlines

Articles On GuruFocus.com
Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
I Believe AstraZeneca Is Fairly Valued Jul 16 2014 
A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
Can Pfizer Make Up Its Loss? May 09 2014 
Abbott Capturing Incremental Market Share Mar 18 2014 
Abbvie's Humira Continues to be a Powerful Catalyst for Growth Mar 18 2014 
10 British Stocks to Consider Feb 20 2014 
Bristol-Myers: Don’t Let This One Get Away Jan 15 2014 
AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is Jan 15 2014 


More From Other Websites
Today's Market Thorns, Roses, and All Time Highs... Sep 23 2014
Top Trades: BBRY & AGN Sep 23 2014
[video] New tax rules from Treasury Sep 23 2014
New tax rules from Treasury Sep 23 2014
US stocks sink amid signs of weaker growth in Europe Sep 23 2014
US tax clampdown paves way for European raid on American corporate jewels Sep 23 2014
AstraZeneca Posts Positive Data on its Type II Diabetes Drug Sep 23 2014
CF Industries rises on merger talks; AstraZeneca, AbbVie fall Sep 23 2014
Stocks Fall To Session Lows; Vipshop Bucks The Trend Sep 23 2014
Pfizer approaches Actavis to gauge interest in deal-Bloomberg Sep 23 2014
Burger King, AbbVie among stocks hit by new tax inversion rules Sep 23 2014
European stocks sink on disappointing eurozone data Sep 23 2014
Treasury inversion crackdown Sep 23 2014
[video] Treasury inversion crackdown Sep 23 2014
Treasury’s new rules won't kill tax inversions: Josh Brown Sep 23 2014
European shares pulled down by disappointing economic data Sep 23 2014
Inversion Crackdown Leaves Several Deals In Limbo Sep 23 2014
Sterling recovers poise after M&A wobble Sep 23 2014
[video] Are tax inversions 'unpatriotic?' Sep 23 2014
FTSE falls, led by pharma, as U.S. tax rules dim M&A prospects Sep 23 2014
Europe shares close lower, after weak PMIs Sep 23 2014
US tax clampdown 'could backfire' Sep 23 2014
Tax clampdown could turn US firms into 'hunted prey' Sep 23 2014
Pharma shares knock FTSE as new U.S. tax rules dent M&A hopes Sep 23 2014
US stocks mixed as European equities tumble Sep 23 2014
Disappointing economic data sends European shares lower Sep 23 2014
AstraZeneca Hurt As Obama Tries To Get Tough On Tax Inversions Sep 23 2014
Why Pfizer (PFE) Stock Is Down Today Sep 23 2014
Stocks to Watch: CarMax, Salix, Spectrum Brands Sep 23 2014
UK profit warnings prompt investor wake-up call Sep 23 2014
Global Tensions and Fear Sep 23 2014
European stocks drop on disappointing eurozone data Sep 23 2014
Tax inversion move: Bitter pill for deals to swallow Sep 23 2014
Pharma shares knock FTSE as new U.S. tax rules dent M&A hopes Sep 23 2014
European shares drop on disappointing economic data Sep 23 2014
Can AstraZeneca plc Help You To Retire Rich? Sep 23 2014
UK tax inversion targets slide following US clampdown Sep 23 2014
Why Shire PLC And AstraZeneca plc Are Falling Today Sep 23 2014
European Stocks Tumble Amid U.S. Clampdown on Tax Inversions Sep 23 2014
Premarkets: 4 things to know before the open Sep 23 2014
Shire, AstraZeneca fall in London after U.S. tax move Sep 23 2014
European shares weaken after disappointing French, German data Sep 23 2014
Nektar says FDA clears constipation drug Movantik Sep 16 2014
Merck 2Q profit more than doubles Jul 29 2014
Bristol 2Q net drops on lower drug sales, charges Jul 24 2014
New study aims to rapidly test lung cancer drugs Jun 17 2014
BofA and Hillshire are big market movers May 27 2014
Nonprescription Nexium heartburn medicine launches May 27 2014
AstraZeneca rejects $119 billion offer from Pfizer May 19 2014
AstraZeneca and AT&T are big market movers May 19 2014
AstraZeneca board rejects new offer from Pfizer May 19 2014
Pfizer raises offer, highlighting flurry of deals May 19 2014
Pfizer ups offer for AstraZeneca again, to $119B May 19 2014
AstraZeneca fends off Pfizer with new growth plan May 06 2014
Pfizer 1Q profit drops 15 pct due to lower sales May 05 2014
Pfizer mulls options after AstraZeneca snubs offer May 05 2014
Stock futures slide after weak Chinese data May 05 2014
AstraZeneca rejects sweetened Pfizer takeover bid May 02 2014
Pfizer sweetens bid for AstraZeneca May 02 2014
Bristol-Myers profit up 54 pct. on cost cuts, sale Apr 29 2014
Bank of America, AstraZeneca are big market movers Apr 28 2014
Pfizer still pursuing AstraZeneca after 2nd rebuff Apr 28 2014
AstraZeneca completes purchase of Sumitomo Chemical’s stake in AstraZeneca K.K. (Japan) Mar 26 2014
Forxiga® receives regulatory approval in Japan for the treatment of type 2 diabetes Mar 24 2014
AstraZeneca proposes appointment of Ann Cairns as Non-Executive Director Mar 20 2014
AstraZeneca announces sale of Alderley Park site in Cheshire, UK Mar 12 2014
US FDA approves Bydureon® Pen (exenatide extended-release for injectable suspension) for... Mar 03 2014
US FDA approves orphan drug MYALEPT™ (metreleptin for injection) Feb 25 2014
AstraZeneca PLC fourth quarter and full year results 2013 Feb 06 2014
AstraZeneca completes the acquisition of Bristol-Myers Squibb share of global diabetes alliance Feb 03 2014
AstraZeneca to shut R&D centre in Bangalore Jan 29 2014
AstraZeneca and Bristol-Myers Squibb Diabetes Alliance Provides $5 Million Grant for American... Jan 16 2014
AstraZeneca provides update at JP Morgan Healthcare Conference on progress to achieve scientific... Jan 14 2014
AstraZeneca and Bristol-Myers Squibb announce US FDA approval of FARXIGA™ (dapagliflozin) Jan 08 2014
AstraZeneca and Bristol-Myers Squibb Announce U.S. FDA Approval of Farxiga™ (dapagliflozin) Jan 08 2014
MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies Jan 08 2014
AstraZeneca and Shionogi settle arbitration and extend licence agreement for CRESTOR® Dec 27 2013
Shionogi Extends License Agreement and Settles Arbitration with AstraZeneca for Crestor® Dec 25 2013
AstraZeneca to acquire Bristol-Myers Squibb share of global diabetes alliance assets Dec 19 2013
AstraZeneca takes control of diabetes venture for $4.1bn Dec 18 2013
AstraZeneca statement in response to reports of a launch of esomeprazole strontium product in the US Dec 17 2013
Aon Hewitt acts as lead advisor on AstraZeneca Pension Fund £2.5bn longevity swap Dec 17 2013
FDA Advisory Committee Recommends the Investigational SGLT2 Inhibitor Dapagliflozin for the... Dec 17 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK